Associate Director, Market Access & Patient Support Marketing - Job ID: ADMA jobs in United States
cer-icon
Apply on Employer Site
company-logo

Ascendis Pharma · 1 month ago

Associate Director, Market Access & Patient Support Marketing - Job ID: ADMA

Ascendis Pharma is a dynamic, fast-growing global biopharmaceutical company advancing programs in Endocrinology Rare Disease and Oncology. They are seeking an experienced Associate Director, Market Access & Patient Support Marketing to develop and execute access strategies ensuring optimal patient and provider access for their products.

BiotechnologyClinical TrialsHealth Care

Responsibilities

Developing and executing access strategies and tactics to ensure optimal patient and provider access for products in the Endocrinology Rare Disease portfolio
Demonstrating strong leadership, project management, and communication skills
Implementing and refining the access marketing plan through innovative thinking and collaboration with cross functional teams such as Market Access, Brand Marketing, Patient Support Services, Sales, Medical Affairs, Finance, Legal, external customers and agency partners

Qualification

Market Access StrategyPatient Support MarketingProject ManagementLeadershipCommunication SkillsInnovative ThinkingCollaboration

Required

Experience in developing and executing access strategies and tactics for biopharmaceutical products
Strong leadership skills
Project management skills
Excellent communication skills
Ability to think innovatively
Collaboration skills with cross-functional teams such as Market Access, Brand Marketing, Patient Support Services, Sales, Medical Affairs, Finance, Legal, external customers, and agency partners

Benefits

Discretionary annual bonus or an incentive compensation plan (eligibility varies based on role and position level)
Discretionary stock-based long-term incentives
Paid time off
Comprehensive benefits package

Company

Ascendis Pharma

twittertwittertwitter
company-logo
Ascendis Pharma built a high-value pipeline that aims to change the clinical treatment paradigms.

Funding

Current Stage
Public Company
Total Funding
$1.88B
Key Investors
Royalty Pharma
2024-09-19Post Ipo Equity· $300M
2024-09-03Post Ipo Debt· $150M
2023-09-05Post Ipo Debt· $150M

Leadership Team

leader-logo
Ivanna Rosendal
Senior Director, IT Business Partner
linkedin
leader-logo
Keren Tenenbaum
US General Counsel and Chief Compliance Officer
linkedin
Company data provided by crunchbase